SCHEMBL18170853

SCHEMBL18170853

Cc1cccc(-c2ccc(NC(=O)c3ccccc3)c3c2CNC3=O)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.75
HDAC2 Q92769 1/20 0.51
ROCK2 O75116 2/20 0.49
RET P07949 2/20 0.49
FLT1 P17948 2/20 0.49
EPHA2 P29317 2/20 0.49
FLT4 P35916 2/20 0.49
FLT3 P36888 2/20 0.49
AURKB Q96GD4 2/20 0.49
AXL P30530 1/20 0.49
FRK P42685 1/20 0.49
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
PLK4 O00444 1/20 0.46
AURKA O14965 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
NTRK1 P04629 1/20 0.46
LCK P06239 1/20 0.46
CSF1R P07333 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18170566 0.94 KDR (0.75) KDRHDAC2ROCK2RETFLT1
SCHEMBL18170622 0.92 KDR (0.71) KDRHDAC2ROCK2RETFLT1
SCHEMBL18170934 0.90 KDR (0.68) KDRHDAC2ROCK2RETFLT1
SCHEMBL18171025 0.90 KDR (0.69) KDRHDAC2AURKBKMT2AMEN1
SCHEMBL18171021 0.89 KDR (0.75) KDRROCK2RETFLT1EPHA2
SCHEMBL18170569 0.89 KDR (0.69) KDRROCK2RETFLT1EPHA2
SCHEMBL18170592 0.89 KDR (0.64) KDRAXLCASP3POLB
SCHEMBL18170453 0.88 KDR (0.63) KDRKMT2AMEN1CASP3KCNK3
SCHEMBL18170637 0.88 KDR (0.68) KDRROCK2RETFLT1EPHA2
SCHEMBL18170712 0.88 KDR (0.63) KDRKMT2AMEN1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US claimed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US claimed
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US disclosed
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME TNIK, TNK1, NFKBIA KDR 1662/4885HDAC2 2231/4885ROCK2 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.